TEVA : Summary for Teva Pharmaceutical Industries - Yahoo Finance

U.S. Markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
34.10+0.35 (+1.04%)
At close: 4:00PM EST

34.09 -0.01 (-0.03%)
After hours: 7:39PM EST

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close33.75
Bid0.00 x
Ask0.00 x
Day's Range33.73 - 34.20
52 Week Range33.56 - 64.31
Avg. Volume10,365,520
Market Cap34.61B
PE Ratio (TTM)22.78
Earnings DateN/A
Dividend & Yield1.36 (4.03%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia10 hours ago

    Teva's Pain Drug Gets Approved By The FDA

    Shares of Teva are up slightly today after the company announced the FDA approved its pain management drug.

  • American City Business Journals10 hours ago

    FDA approves Teva's abuse-deterrent painkiller

    The Food and Drug Administration granted marketing approval Wednesday to Vantrela ER, an extended release pain medicine developed by Teva Pharmaceutical Industries that is formulated using the company’s proprietary abuse deterrence technology. Vantrela ER was approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Company officials said the product’s abuse-deterrent properties that are expected to reduce, but not totally prevent, oral, intranasal and intravenous abuse of the drug when the tablets are manipulated.

  • Business Wire13 hours ago

    Teva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets Formulated with Proprietary Abuse Deterrence Technology

    Teva Pharmaceutical Industries Ltd. today announced the U.S. Food and Drug Administration approved VANTRELATM ER extended-release tablets formulated with Teva’s proprietary abuse deterrence technology.